Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Novartis
- 26 Sep 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 13 Apr 2016 Status changed from not yet recruiting to recruiting.